216 related articles for article (PubMed ID: 28668277)
1. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.
Yu SS; Athreya K; Liu SV; Schally AV; Tsao-Wei D; Groshen S; Quinn DI; Dorff TB; Xiong S; Engel J; Pinski J
Clin Genitourin Cancer; 2017 Dec; 15(6):742-749. PubMed ID: 28668277
[TBL] [Abstract][Full Text] [Related]
2. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.
Liu SV; Tsao-Wei DD; Xiong S; Groshen S; Dorff TB; Quinn DI; Tai YC; Engel J; Hawes D; Schally AV; Pinski JK
Clin Cancer Res; 2014 Dec; 20(24):6277-83. PubMed ID: 25278449
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
4. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
Emons G; Gorchev G; Harter P; Wimberger P; Stähle A; Hanker L; Hilpert F; Beckmann MW; Dall P; Gründker C; Sindermann H; Sehouli J
Int J Gynecol Cancer; 2014 Feb; 24(2):260-5. PubMed ID: 24418927
[TBL] [Abstract][Full Text] [Related]
6. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
10. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
11. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
16. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
